The Intellectual Property Red Line Three hundred patents, primarily focused on quantum entanglement processing, just became the flashpoint for a new global tech war. Yesterday, in an unprecedented coordinated action, regulatory bodies spanning the European Read More
The Ejection Heard ‘Round the Biomedical World Forcing five leading scientists, including the editor-in-chief of its flagship journal, from an annual meeting for distributing an opinion piece critiquing political actions is not merely a public Read More
The Unsettling Silence from Regulators A leading regulatory body, the U.S. Food and Drug Administration, has confessed it cannot identify the origin of a deadly pathogen in one of the most sensitive products imaginable: Read More
The Invisible Wall: Tech’s Biosecurity Blind Spot The recent confirmation of New World screwworm in South Texas isn’t just an agricultural headache; it’s a stark, squirming indictment of where the global technology Read More
The Price of Platform Agility Fifty million dollars just landed in Moderna’s accounts, courtesy of the Coalition for Epidemic Preparedness Innovations (CEPI), earmarked for the early-stage development of an mRNA vaccine against Bundibugyo ebolavirus. Read More
Fragmented Oversight: A Missed Tech Opportunity The proposed shift to state-level enforcement for coal ash cleanup, spearheaded by the Trump administration and fiercely opposed by environmental groups at a recent EPA public comment hearing, is Read More
The Algorithmic Amplification of Neglect A child lies hospitalized in West Texas, a victim not just of a resurgent measles virus, but of an algorithmic flaw. The recent postmortem in the Morbidity and Mortality Weekly Read More
The Cost of Outsourcing Health Responsibility A Kenyan court’s swift decision to block the Trump administration’s plan to offload Ebola-exposed American citizens onto its soil exposes more than just a diplomatic spat. It Read More
The Costly Illusion of American Health While Silicon Valley basks in the glow of AI breakthroughs and venture capital inflows, a different kind of abysmal number dropped this week, one that quietly corrodes America’s Read More
Beyond the Headlines: A Single Dose, A Multi-Decade Question The immediate euphoria surrounding VERVE-102’s interim Phase I results—a staggering 62 percent reduction in LDL cholesterol—misses the most critical elephant in the biotech lab. Read More